« Back
Home /
AZD4573

AZD4573

Item no.	HY-112088-5mg
Manufacturer	MedChem Express
CASRN	2057509-72-3
Amount	5 mg
Quantity options	100 mg 10 mM/1 mL 10 mg 1 mg 25 mg 50 mg 5 mg
Category	Metabolism Diabetes Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Purity	99.98
Citations	[1]Bernard Barlaam, et al. Abstract 1650: Discovery of AZD4573, a potent and selective inhibitor of CDK9 that enables transient target engagement for the treatment of hematologic malignancies. Cancer Research. July 2018. 78(13): Supplement.
Smiles	ClC1=CN=C(NC([C@H]2CCC[C@@H](NC(C)=O)C2)=O)C=C1C3=C(CC(C)(C)C4)N4N=C3
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	2057509-72-3
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-Kinase/protease
Manufacturer - Targets	CDK
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	429.94
Product Description	AZD4573 is a potent and highly selective CDK9 inhibitor (IC50 of [1].
Manufacturer - Research Area	Cancer
Solubility	DMSO : 50 mg/mL (ultrasonic)
Manufacturer - Pathway	Cell Cycle/DNA Damage
Clinical information	Phase 2
Isoform	CDK9

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.